Edwards Lifesciences Stock Rises On Beat-And-Raise, Announces CFO Transition

Edwards Life Sciences (EW) raised its 2025 outlook late Thursday, helped by a broad beat that included double-digit growth for its high-profile transcatheter heart valve replacement business.

Transcatheter heart valve replacement, or TAVR, is a non-surgical way to replace a defective catheter valve in the heart. TAVR sales rose more than 12% — or nearly 11% in constant currency — to $1.15 billion. That easily beats expectations of $1.1 billion, according to FactSet.

The strong sales follow a study unveiled this week that showed superior clinical outcomes after a year for patients who underwent transcatheter aortic valve replacement instead of surgery to replace their valves. These are patients who are considered to be at lower risk of complications due to open heart surgery.

Separately, a decade-long study painted a similar picture of TAVR patients at average risk of undergoing surgery.

“TAVR continues to benefit from the halo effect from the presentation of (a study called) EARLY TAVR data in late 2024 that refocuses cardiac teams on TAVR,” William Blair analyst Brandon Vasquez said in a report. “Because asymptomatic patients are not yet covered by CMS, we believe the real benefits of TAVR growth will come in 2026.”

Edwards Lifesciences stock fell 1.2% on Friday, closing at 82.45. MarketSurge chart analysis shows that shares fell below the buy zone after breaking out of a flat base with an entry at 83.

Edwards’ wide win

Overall, Edwards reported adjusted earnings of 67 cents per share on sales of $1.55 billion for the third quarter. Profits rose 12% with sales up nearly 15%. On an adjusted basis, sales were up approximately 13%. Both measures beat expectations by 60 cents and $1.5 billion, respectively.

Outside of TAVR, revenue from Edwards’ non-surgical means of replacing mitral and tricuspid valves in the heart, or TMTT, rose more than 59% to $145.2 million. Analysts expected this division’s sales to decline by $142.1 million.

In response to this strong quarter, Edwards increased its sales forecast. The company now sees sales rising at the high end of a 9% to 10% range, but did not provide a specific number. It also calls for adjusted earnings of $2.56 to $2.62 per share. At the midpoint, that’s 9 cents per share above the guidance Edwards issued three months ago.

Analysts expected $2.51 earnings per share and $5.98 billion in sales.

Edwards also announced that CFO Scott Ohlem has decided to transition from his position by mid-2026. The company will conduct a selection process to select a new CFO.

Follow Alison Gatlin on X/Twitter at @AGatlin_IBD.

You may also like:

Why Guardant Health’s IBD 50 Is Up 137% in 2025 Again

Novo Nordisk begins a bloody battle with Pfizer and makes a $6.5 billion offer to buy Metsira

IBD Stock of the Day: Learn how to find, track and buy the best stocks

Options trading: How to start using options, and how to manage risk

Review IBD stock listings and get pass/fail ratings for all your stocks with IBD Digital